SCHEMBL4665197

SCHEMBL4665197

CN(C)S(=O)(=O)c1cccc(Br)c1C(F)(F)F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ HTT P42858 1/20 0.40
▸ POLB P06746 2/20 0.40
▸ HSD11B1 P28845 1/20 0.37
▸ LMNA P02545 1/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ CA1 P00915 2/20 0.36
▸ CA2 P00918 2/20 0.36
▸ CA4 P22748 1/20 0.36
▸ CA6 P23280 1/20 0.36
▸ ABCC9 O60706 1/20 0.35
▸ ABCC8 Q09428 1/20 0.35
▸ KCNJ11 Q14654 1/20 0.35
▸ KCNJ8 Q15842 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ GSTO1 P78417 2/20 0.35
▸ KCNJ6 P48051 2/20 0.35
▸ KCNJ3 P48549 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28088573 0.81 CA1 (0.39) POLBHSD11B1KMT2ATDP1CA1
SCHEMBL4314526 0.77 CA2 (0.39) ALDH1A1HSD11B1KMT2ATDP1CA1
SCHEMBL2782423 0.77 ALDH1A1 (0.45) ALDH1A1SMN1; SMN2HTTPOLBLMNA
SCHEMBL9577231 0.77 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2HTTPOLBLMNA
SCHEMBL29558069 0.76 CA1 (0.56) ALDH1A1SMN1; SMN2HTTPOLBHSD11B1
SCHEMBL4518646 0.76 CA1 (0.56) ALDH1A1SMN1; SMN2HTTPOLBHSD11B1
SCHEMBL29452062 0.75 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2HTTPOLBLMNA
SCHEMBL17187964 0.72 KMT2A (0.39) ALDH1A1SMN1; SMN2POLBKMT2ACA1
SCHEMBL9866404 0.72 ALDH1A1 (0.35) ALDH1A1SMN1; SMN2HTTPOLBLMNA
SCHEMBL27642658 0.72 MEN1 (0.51) ALDH1A1SMN1; SMN2HTTPOLBHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080021039-A1 Imidazopyridine-derivatives as inducible no-synthase inhibitors ALTANA PHARMA AG 2008-01-24 — — US disclosed
US-7279488-B2 Imidazopyridine-derivatives as inducible no-synthase inhibitors NYCOMED GMBH (DE) 2007-10-09 — — US disclosed
US-20060293302-A1 Imidazopyridine-derivatives as inducible no-synthase inhibitors ALTANA PHARMA AG (DE) 2006-12-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060293302-A1 Imidazopyridine-derivatives as inducible no-synthase inhibitors NOS2, NOS1, NOS3 ALDH1A1 383/4885SMN1; SMN2 4215/4885HTT 4616/4885
US-20080021039-A1 Imidazopyridine-derivatives as inducible no-synthase inhibitors NOS2, NOS1, NOS3 ALDH1A1 383/4885SMN1; SMN2 4215/4885HTT 4616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback